채영광 (Northwestern University Feinberg School of Medicine)님 | 한빛사연구자 > 한빛사

Northwestern University Feinberg School of Medicine

CV File

최종업데이트 2026.02.14.

- ( 현재 등록 진행중입니다. )
- 채영광(Northwestern University Feinberg School of Medicine)
- 류지연(Northwestern University Feinberg School of Medicine)
- 이세영(Northwestern University Feinberg School of Medicine)
- 백승원(Northwestern University Feinberg School of Medicine)
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)
- J. Immunother. Cancer, Mar 11 2026, 14 (3) e013260 | https://doi.org/10.1136/jitc-2025-013260
- 2026-03
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy
- J. Immunother. Cancer, Feb 20 2026, 14 (2) e013391 | https://doi.org/10.1136/jitc-2025-013391
- 2026-02
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
- J. Immunother. Cancer, 11 February 2026 | doi:10.1136/jitc-2025-012805
- 2026-02
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38)
- J. Immunother. Cancer, Oct 20 2025, 13 (10) e013147 | https://doi.org/10.1136/jitc-2025-013147
- 2025-10
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction
- J. Immunother. Cancer, 4 August 2025 | https://doi.org/10.1136/jitc-2024-011346
- 2025-08
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort
- J. Immunother. Cancer, Jun 30 2025, 13 (6) e011760 | https://doi.org/10.1136/jitc-2025-011760
- 2025-06
- 의약학
- 한빛사논문
Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates
- Cancer Metastasis Rev., Jun 27 2025, 44 (3) | https://doi.org/10.1007/s10555-025-10274-2
- 2025-06
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
  Interview
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
- Cancer Commun., May 22 2025, | https://doi.org/10.1002/cac2.70020
- 2025-05
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
  Interview
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vulvar Cancers
- Clin. Cancer Res., Nov 19 2024, | https://doi.org/10.1158/1078-0432.CCR-24-1957
- 2024-11
- 의약학
- 한빛사논문
- 채영광(Northwestern University Feinberg School of Medicine)
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer
- Clin. Cancer Res., Oct 17 2024, | https://doi.org/10.1158/1078-0432.CCR-24-0606
- 2024-10
- 의약학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기